IL10 and COVID-19: Previous studies have reported that the elevation in IL-6, IL-10, and IFN-γ levels in CRS, including CAR T cell therapy and severe COVID-19, is a typical phenomenon in HLH/MAS, wherein activated macrophages or T cells are the major producers of proinflammatory cytokines (26, 27).